Smoking and IPMN malignant progression

R. A. Carr, A. M. Roch, K. Shaffer, S. Aboudi, C. M. Schmidt, John DeWitt, E. P. Ceppa, Michael House, Nicholas Zyromski, Attila Nakeeb, C. Schmidt

Research output: Contribution to journalArticle

5 Scopus citations


Background: Patients with intraductal papillary mucinous neoplasm (IPMN) are at risk for invasive pancreatic cancer. We aim to characterize the impact of smoking on IPMN malignant progression. Methods: Patients undergoing pancreatic resection for IPMN (1991-2015) were retrospectively reviewed using a prospectively collected database. Results: Of 422 patients identified, 324 had complete data for analysis; 55% were smokers. Smoking status did not impact IPMN malignant progression (smokers/non-smokers: 22%/18% invasive grade; p = 0.5).Smokers were younger than non-smokers at the time of IPMN diagnosis (63 versus 68 years; p = 0.001). This association also held in the invasive IPMN subgroup (65 versus 72 years, p = 0.01). Despite this observation, rate of symptoms at diagnosis, cancer stage, and median survival were the same between smokers and non-smokers. Conclusion: Although smoking is not associated with IPMN malignant progression, invasive IPMN is diagnosed at a younger age in smokers. These data suggest tobacco exposure may accelerate IPMN malignant progression.

Original languageEnglish (US)
JournalAmerican Journal of Surgery
StateAccepted/In press - Jul 25 2016



  • Age
  • Intraductal papillary mucinous neoplasm (IPMN)
  • Smoking

ASJC Scopus subject areas

  • Surgery

Cite this